Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Neurochem Int. 2011 Dec 30;60(3):215–219. doi: 10.1016/j.neuint.2011.12.011

Fig. 1.

Fig. 1

Mean clinical disease score in GMF-KO and Wt mice treated with rGMF (0.5 μg/g/day) was injected i.p. every day, starting at day 0 until day 14 after immunization with MOG35–55 peptide. EAE in mice was scored as follows: score 0, no disease; score 1, tail weakness; score 2, weakness in hind limb; score 3, complete hind limb paralysis; score 4, hind limb paralysis with fore limb weakness or paralysis; and score 5, moribund or deceased. Each graph presents mean clinical severity scores from eight to ten mice per group.